Gline Matthew (CIK 1750094) reported 17 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell ROIV (76,171 shares), Sell ROIV (289,774 shares), Buy ROIV (234,096 shares), Sell ROIV (230,357 shares), Sell ROIV (3,739 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 76,171 | $2.7M |
| 2026-04-20 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 289,774 | $8.4M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 234,096 | $950,430 |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 230,357 | $5.0M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 3,739 | $81,062 |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 1.4M | $17.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 566,116 | $12.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 797,595 | $17.3M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 2.3M | $28.8M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 943,527 | $20.5M |
| 2025-12-17 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 1.3M | $28.8M |
| 2025-09-18 | Roivant Sciences Ltd. (ROIV) | CEO | Buy | 3,315 | $49,957 |
| 2025-05-22 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $120,833 |
| 2025-04-22 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $111,092 |
| 2025-03-24 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $120,067 |
| 2025-02-24 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 10,945 | $117,330 |
| 2025-01-22 | Roivant Sciences Ltd. (ROIV) | CEO | Sell | 11,623 | $129,596 |
Source: SEC Form 4 filings · as of 2026-07-02